Patients whose physicians “collaborate” with genetic testing corporations should beware. Today, Navigenics and all genetic testing businesses can legally sell genomic data. There is no way to know which ones sell or use data without informed consent and which don’t. Americans’ personal health information is extremely valuable to corporate America. Genomic data requires extreme privacy protection because it can be used to harm not only an individual but all his/her relatives.
According to Navigenics, the personal data shared is “aggregated” and “de-linked” from “your account information”, but Navigenics offers no proof that it cannot be re-identified.
As we learned from the NIH experience, it is very difficult to “de-identify” or “anonymize” genetic data. The NIH closed a public research data base of “de-identified” genetic data after researchers proved the data could be re-identified See: . Corporations that share “de-identified” or “anonymized” health data should be required to publish the algorithms that were used and prove the data cannot be re-identified.
• How can anyone be sure that Navigenics protects the privacy of genomic tests without trusted external audits of their privacy practices and policies?
• Does Navigenics pay MDVIP’s doctors a “kickback” for “collaborating” each time a patient gets genomic tests? Does MDVIP inform patients that it has a contract with Navigenics and what each doctor is paid?
• Who is being paid for “collaboration”? What exactly are the financial and contractual terms of “collaboration” between MDVIP and Navigenics?
• Do MDVIP’s patients really understand the risks of using Navigenics to do the testing or the risks of letting Navigenics share their genomic data with unknown researchers and research organizations—-that can put their data into public data respositories and publish it in studies? Or the security risks that a particular public respository can be hacked?
• Are MDVIP’s patients coreced into taking Navigenics tests by their doctors? Most patients want to do what their doctors recommend. What is the consent process?
• Did MDVIP contractually sell or give their patients’ genomic data or to Navigenics to own or sell? Should the public trust Navigenics, a for-profit corporation, when personal genomic data is a very valuable commodity?
• Should any for-profit collaboration “define the standards in which preventive genomic medicine will be integrated into patient care for decades to come”? No consumer health privacy expertise, assessment, or input was sought.
• There is not yet an operational, trusted, consumer-led privacy certification organization to audit genomic testing corporations to certify they don’t sell genomic data and that consumers control sensitive personal genomic data in their data bases. In the absence of a trusted privacy certification organization, the privacy principles developed in 2007 by the bipartisan Coalition for Patient Privacy or the Code of Fair Information Practices could be used as guides for building a genomic testing and preventive healthcare system that consumers will trust and be willing to use.
• Would MDVIP’s patients still feel “the experience (was) positive”, “empowered rather than anxious”, and “desire to change their lifestyles and more productively work with their physicians” if they knew their doctors were paid by Navigenics and their data was sold and/or put in public data repositories with unknown security and privacy protections?
This blog is in response to the article: Physician network to use genomic-based preventive healthcare